首页 | 本学科首页   官方微博 | 高级检索  
     

全天麻胶囊联合尼莫地平治疗偏头痛的临床研究
引用本文:吴俏丽,郭金薪,金国芳,黄晓刚,胡双双. 全天麻胶囊联合尼莫地平治疗偏头痛的临床研究[J]. 现代药物与临床, 2024, 39(2): 362-366
作者姓名:吴俏丽  郭金薪  金国芳  黄晓刚  胡双双
作者单位:上海市松江区泗泾医院 药剂科, 上海 201601;上海市松江区泗泾医院 内科, 上海 201601;上海市第七人民医院(上海中医药大学附属第七人民医院), 上海 2001374
基金项目:上海市科技计划项目(20YF1437100k)
摘    要:目的 探讨全天麻胶囊联合尼莫地平片治疗偏头痛的临床疗效。方法 选取2021年2月—2023年4月上海市松江区泗泾医院收治的88例偏头痛患者,根据随机数字表法将所有患者分为对照组和治疗组,各44例。对照组口服尼莫地平片,2片/次,3次/d。治疗组在对照组基础上口服全天麻胶囊,6粒/次,3次/d。两组连续治疗12周。比较两组的治疗效果、偏头痛症状、脑部血流动力学指标和血清指标。结果 治疗后,治疗组的总有效率比对照组高,差异有统计学意义(P<0.05)。治疗后,两组的发作频率、每次持续时间、VAS评分低于治疗前(P<0.05);治疗组的发作频率、每次持续时间、VAS评分低于对照组(P<0.05)。治疗后,两组脑部前动脉、中动脉、后动脉的平均血流速度均显著降低(P<0.05);治疗组的脑部前动脉、中动脉、后动脉的平均血流速度低于对照组(P<0.05)。治疗后,两组的血清基质金属蛋白-9(MMP-9)水平显著降低,血清P物质(SP)、β-内啡肽(β-EP)水平显著升高(P<0.05);治疗后,治疗组的血清MMP-9水平低于对照组,血清SP、β-EP水平高于对照...

关 键 词:全天麻胶囊  尼莫地平片  偏头痛  发作频率  每次持续时间  VAS评分  平均血流速度  基质金属蛋白-9  P物质  β-内啡肽
收稿时间:2023-11-19

Clinical study on Quantianma Capsules combined with nimodipine in treatment of migraine
WU Qiaoli,GUO Jinxin,JIN Guofang,HUANG Xiaogang,HU Shuangshuang. Clinical study on Quantianma Capsules combined with nimodipine in treatment of migraine[J]. Drugs & Clinic, 2024, 39(2): 362-366
Authors:WU Qiaoli  GUO Jinxin  JIN Guofang  HUANG Xiaogang  HU Shuangshuang
Affiliation:Department of Pharmacy, Shanghai Songjiang District Sijing Hospital, Shanghai 201601, China;Department of Internal Medicine, Shanghai Songjiang District Sijing Hospital, Shanghai 201601, China; Shanghai Seventh People''s Hospital (Seventh People''s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine), Shanghai 2001374, China
Abstract:Objective To investigate the clinical effect of Quantianma Capsules combined with Nimodipine Tablets in treatment of migraine. Methods Patients (88 cases) with migraine in Shanghai Songjiang District Sijing Hospital from February 2021 to April 2023 were divided into control and treatment groups according to the random number table method, and each group had 44 cases. Patients in the control group were po administered with Nimodipine Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Quantianma Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies, migraine symptom, cerebral hemodynamic indexes, and serum indexes in two groups were compared. Results After treatment, the total effective rate of the treatment group was higher than that of the control group, and the difference was statistically significant (P < 0.05). After treatment, the frequency and duration of migraine attacks and VAS scores of two groups were lower than those before treatment (P < 0.05), and the frequency and duration of migraine attacks and the VAS scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the average blood flow velocity of anterior, middle, and posterior cerebral arteries was significantly decreased in two groups (P < 0.05), and the average blood flow velocity of anterior, middle, and posterior cerebral arteries in the treatment group was lower than those in the control group (P < 0.05). After treatment, the serum levels of MMP-9 in two groups were significantly decreased, but the serum levels of SP and β-EP in two groups were significantly increased (P < 0.05). After treatment, the serum levels of MMP-9 in the treatment group was lower than those in the control group, but the serum levels of SP and β-EP in the treatment group were higher than those in the control group (P < 0.05). Conclusion Quantianma Capsules combined with Nimodipine Tablets can improve the curative effect of migraine, can reduce the clinical effect, improve the level of cerebral hemodynamics, and improve serum indexes.
Keywords:Quantianma Capsules  Nimodipine Tablets  migraine  frequency  duration  VAS score  average blood flow velocity  MMP-9  SP  β-EP
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号